Research Progress of PD-L1 Expression in Circulating Tumor Cells in Malignant Tumors
10.3971/j.issn.1000-8578.2022.21.0648
- VernacularTitle:循环肿瘤细胞PD-L1表达在恶性肿瘤中的研究进展
- Author:
Zuxi LI
1
;
Xianbin HUANG
;
Yuntao MA
;
Weipeng ZHAN
;
Ming HU
;
Hongwei TIAN
;
Jing YANG
Author Information
1. The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Circulating tumor cell;
Liquid biopsy;
Prognosis judgment;
Efficacy evaluation;
Immunotherapy monitoring
- From:
Cancer Research on Prevention and Treatment
2022;49(3):225-229
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, with the in-depth study of PD-1 and PD-L1 and the development of immunotherapy, the first problem is how to screen the beneficiaries. Recent clinical studies have shown that the expression level of PD-L1 in circulating tumor cells (CTC) can be used as a potential biomarker to play a guiding role in immunotherapy of malignant tumors. This article reviews the latest clinical research progress on the expression of PD-L1 in circulating tumor cells in various solid tumors.
